ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

Benzinga_recent_news04-01

ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) surged during Tuesday's session before pulling back sharply in after-hours trading following the release of new clinical data for its lead drug candidate. ORIC ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624756770?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/01/Medication-In-Transparent-Capsules-On-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-01 14:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624756770","market":"sh","top_or_hot":-1,"title":"ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?","media":"Benzinga_recent_news","content":"<div>\n<p>ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) surged during Tuesday's session before pulling back sharply in after-hours trading following the release of new clinical data for its lead drug candidate.\nORIC ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 14:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) surged during Tuesday's session before pulling back sharply in after-hours trading following the release of new clinical data for its lead drug candidate.\nORIC ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORIC","symbol_name":"Oric Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on","article_id":"2624756770","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/01/Medication-In-Transparent-Capsules-On-A-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51590748/oric-pharmaceuticals-stock-nosedives-25-percent-after-hours-what-is-going-on","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624756770","pubTimestamp":1775026080,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3 trial, before falling sharply in after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORIC":"Oric Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"ORIC Pharmaceuticals股价盘后暴跌25%：这是怎么回事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORIC":1.5},"content_text":"ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) surged during Tuesday's session before pulling back sharply in after-hours trading following the release of new clinical data for its lead drug candidate.\nORIC closed the regular session up 3.94% at $12.67 but fell 24.86% after hours to $9.52.\nORIC Pharmaceuticals is a clinical-stage biotech company focused on developing therapies to overcome resistance in cancer treatment. The stock has gained over 120% in the past year, trading between a 52-week low of $3.90 and a high of $14.93.\nThe company reported updated Phase 1b data for rinzimetostat (ORIC-944) in combination with darolutamide for patients with metastatic castration-resistant prostate cancer. At a median follow-up of approximately five months, the treatment demonstrated a radiographic progression-free survival rate of 84%, alongside favorable safety outcomes.\nORIC also selected a 400 mg once-daily dose as the recommended Phase 3 dose and said it expects to initiate its global Phase 3 Himalayas-1 trial in the first half of 2026. The study is expected to enroll approximately 600 patients across more than 20 countries.\nDespite the positive data and advancement toward a late-stage trial, shares declined in after-hours trading, suggesting investor caution around early-stage results or profit-taking following the recent run-up.\nORIC Pharmaceuticals has a market capitalization of approximately $1.27 billion. The stock's 52-week high is $14.93, and its 52-week low is $3.90.\nBenzinga Edge Rankings indicate ORIC Pharmaceuticals stock shows positive price trends across short, medium and long-term periods.\nDisclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.\nPhoto Courtesy: Alexandr Popel on Shutterstock.com\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624756770","isCrawlerRequest":true}